AzTrials
AzTrials

Healthy Adults; Cognitive Performance; Sleep Quality; Neuromuscular FunctionNCT07706283

Sex-Divergent Effects of Magnesium L-Threonate Supplementation on Sleep Quality, Cognitive Performance, and Neuromuscular Function in Healthy Adults

A study testing Magnesium L-threonate in people with Healthy Adults; Cognitive Performance; Sleep Quality; Neuromuscular Function, run by Barry University at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This study examined the effects of six weeks of magnesium L-threonate (MgT) supplementation on sleep quality, cognitive performance under experimentally induced mental fatigue, neuromuscular function, and psychophysiological outcomes in healthy adults. Read more about this study

Who is it for?
Ages 18 to 45 yearsHealthy volunteers can take part
What is being tested?
Magnesium L-threonate
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
81 participants
Where
1 siteUnited States
Study dates
1 Dec 2025to 19 Mar 2026
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 45 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Healthy male or female adults aged 18-45 years
  • Free from diagnosed neurological, cardiovascular, metabolic, or psychiatric conditions
  • Not currently taking medications or supplements known to influence cognitive or neuromuscular function
  • Willing to maintain habitual diet, physical activity, and sleep routines throughout the study period

Who cannot join

  • Pregnant or breastfeeding
  • Diagnosed sleep disorder
  • Initiated any new supplement or medication regimen within the past three months
  • Failed to meet ≥85% supplementation adherence threshold during the study (post-enrollment exclusion)
  • Technical data malfunction resulting in unrecoverable testing data (post-enrollment exclusion)
  • Identified as a multivariate outlier (values exceeding ±3 SD from the group mean on primary outcomes; post-enrollment exclusion)

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Barry University

    Miami Shores, Florida, 33161

Other trials in United States

About this study

Official title: Sex-Divergent Effects of Magnesium L-Threonate Supplementation on Sleep Quality, Cognitive Performance Under Mental Fatigue, and Neuromuscular Function in Healthy Adults: A Randomized, Double-Blind, Placebo-Controlled Trial

This study examined the effects of six weeks of magnesium L-threonate (MgT) supplementation on sleep quality, cognitive performance under experimentally induced mental fatigue, neuromuscular function, and psychophysiological outcomes in healthy adults. Biological sex and weight status were examined as pre-specified moderating variables.

Read the detailed description

This study was a randomized, double-blind, placebo-controlled, parallel-group trial examining the effects of six weeks of magnesium L-threonate (MgT) supplementation on cognitive performance, mental fatigue, neuromuscular function, sleep quality, and psychophysiological outcomes in healthy adults. Biological sex and weight status were examined as pre-specified moderating variables given evidence for sex-specific differences in magnesium homeostasis and the elevated prevalence of magnesium inadequacy in individuals with overweight or obesity.

Participants:

Healthy male and female adults aged 18-45 years were recruited from a local university and surrounding community. Eighty-one participants were enrolled and randomized; the final analytic sample comprised 54 participants (MgT: n = 28; PLA: n = 26) following exclusions for non-adherence, technical data malfunction, and multivariate outlier removal. The sample was 59% female with a mean age of 23 ± 6 years and mean BMI of 26.7 ± 6.3 kg/m².

Intervention:

Participants assigned to the intervention group consumed 2 g·day-¹ of magnesium L-threonate (Magtein®; AIDP Inc., City of Industry, CA, USA) divided into two daily doses (morning and evening) for six weeks. Participants assigned to the placebo group consumed visually identical capsules containing rice powder (2 g·day-¹) on the same dosing schedule. Supplement compliance was assessed via capsule count at study conclusion; participants demonstrating less than 85% adherence were excluded from the final analytic sample.

Testing Procedures:

Participants completed identical testing sessions at baseline (Week 0) and following six weeks of supplementation (Week 6). All sessions were conducted at the same time of day for each participant to minimize circadian variability. Prior to each session, participants were instructed to abstain from caffeine for at least 12 hours, alcohol for 24 hours, and strenuous exercise for 24 hours.

Testing was conducted in a standardized order as follows:

Psychophysiological Questionnaires: Participants completed the Pittsburgh Sleep Quality Index (PSQI; 0-21 scale), Perceived Stress Scale (PSS), State-Trait Anxiety Inventory (STAI; state and trait subscales), and Visual Analog Scale for Fatigue (VAS-F; 0-100 mm) prior to any physical or cognitive testing.

Neuromuscular Assessment - Pre-fatigue: Countermovement jump (CMJ) performance was assessed using dual force plates (VALD ForceDecks, VALD Performance, Brisbane, Australia). Variables of interest included jump height (cm), peak landing force (N), reactive strength index (m·s-¹), and concentric impulse (N·s).

Cognitive Battery - Pre-fatigue: Cognitive performance was assessed using a computerized battery administered via the SOMA platform (SOMA Technologies, Lucerne, Switzerland). The battery included four tasks: the Psychomotor Fatigue Test (PFTT), Incongruent Flanker Task, Incongruent Stroop Task, and Task-Switching Test. Primary cognitive outcomes included reaction time (RT; ms), processing speed (1000/RT; s-¹), coefficient of variation (%), and rate correct score (correct responses·s-¹) derived from each task.

Mental Fatigue Induction: Mental fatigue was induced via a standardized 20-minute time-load dual-back (TLDB) task. The VAS-F was administered immediately before and after the TLDB task to quantify changes in perceived fatigue. The NASA Task Load Index (NASA-TLX) was completed immediately following the TLDB task to assess subjective cognitive workload across six subscales: mental demand, physical demand, temporal demand, performance, effort, and frustration.

Cognitive Battery - Post-fatigue: The full cognitive battery was repeated immediately following the TLDB protocol to assess performance under conditions of experimentally induced cognitive fatigue.

Neuromuscular Assessment - Post-fatigue: CMJ testing was repeated following the post-fatigue cognitive battery to assess the effect of cognitive load on subsequent neuromuscular output.

Statistical Analysis All analyses were performed in R with statistical significance set at α = 0.05. Primary outcomes were analyzed across three structurally distinct approaches: (1) absolute outcomes and within-bout change scores (pre- to post-mental fatigue) at W0 and W6 were analyzed using linear mixed models with fixed effects of condition, time, the condition-by-time interaction, and a random intercept for participant; (2) six-week change scores (W6 - W0) were analyzed using ANOVA with fixed effects of condition, sex, weight status, and the corresponding two- and three-way interactions; and (3) the change in the within-bout mental fatigue response across the six-week period was analyzed using analogous ANOVA to isolate whether MgT altered the magnitude of the acute mental fatigue response over time. Significant interaction effects were further assessed using post hoc comparisons with Bonferroni-Holm adjustment. Unadjusted simple effects tests were conducted when omnibus interactions were significant but adjusted post hoc comparisons were not, and are reported as exploratory. All primary models were re-estimated following removal of values exceeding ±3 SD to evaluate robustness of findings.

Being tested
Magnesium L-threonate, Placebo
Keywords
magnesium L-threonate, mental fatigue, sleep quality, neuromuscular function, sex differences, countermovement jump, cognitive performance, ergogenic supplementation
Medical subject headings
Sleep Initiation and Maintenance Disorders, Mental Fatigue

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Magnesium L-threonateDietary supplement

    Also called Magtein®

    Magnesium L-threonate

  • PlaceboDietary supplement

    Rice powder

Study groups in NCT07706283
Study groupRoleWhat they receive
Magnesium L-Threonate (MgT)ExperimentalParticipants consumed 2 g·day-¹ of magnesium L-threonate (Magtein®; AIDP Inc., City of Industry, CA, USA) once daily for six weeks.
Receives: Dietary Supplement: Magnesium L-threonate
PlaceboPlacebo comparatorParticipants consumed visually identical capsules containing rice powder (1.4 g·day-¹) once daily for six weeks. Capsules were matched to the intervention in appearance and dosing schedule.
Receives: Dietary Supplement: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Pittsburgh Sleep Quality Index (PSQI)

    Subjective sleep quality assessed using the Pittsburgh Sleep Quality Index (PSQI; scored 0-21). Higher scores indicate poorer sleep quality. A score ≥5 indicates poor sleep quality.

    Measured: Baseline (Week 0) and post-intervention (Week 6)

  2. Flanker Task Reaction Time

    Reaction time (ms) on the Incongruent Flanker Task assessed via computerized cognitive battery (SOMA platform). Lower values indicate faster processing.

    Measured: Baseline (Week 0) and post-intervention (Week 6), assessed before and after a 20-minute mental fatigue induction protocol at each visit

  3. Countermovement Jump Height

    Jump height (cm) assessed via dual force plates (VALD ForceDecks). Higher values indicate greater neuromuscular performance.

    Measured: Baseline (Week 0) and post-intervention (Week 6), assessed before and after a 20-minute mental fatigue induction protocol at each visit

Secondary outcomes (22)
  1. Flanker Task Processing Speed

    Processing speed (1000/RT; s-¹) on the Incongruent Flanker Task. Higher values indicate faster processing.

    Measured: Baseline (Week 0) and post-intervention (Week 6), assessed before and after mental fatigue induction

  2. Flanker Task Rate Correct Score

    Rate correct score (correct responses·s-¹) on the Incongruent Flanker Task. Higher values indicate better integrated speed-accuracy performance.

    Measured: Baseline (Week 0) and post-intervention (Week 6), assessed before and after mental fatigue induction

  3. Flanker Task Coefficient of Variation

    Intraindividual response variability (%) on the Incongruent Flanker Task. Lower values indicate more consistent performance.

    Measured: Baseline (Week 0) and post-intervention (Week 6), assessed before and after mental fatigue induction

  4. Stroop Task Reaction Time

    Reaction time (ms) on the Incongruent Stroop Task assessed via computerized cognitive battery. Lower values indicate faster processing.

    Measured: Baseline (Week 0) and post-intervention (Week 6), assessed before and after mental fatigue induction

  5. Stroop Task Processing Speed

    Processing speed (1000/RT; s-¹) on the Incongruent Stroop Task. Higher values indicate faster processing.

    Measured: Baseline (Week 0) and post-intervention (Week 6), assessed before and after mental fatigue induction

  6. Stroop Task Rate Correct Score

    Rate correct score (correct responses·s-¹) on the Incongruent Stroop Task. Higher values indicate better integrated speed-accuracy performance.

    Measured: Baseline (Week 0) and post-intervention (Week 6), assessed before and after mental fatigue induction

  7. Psychomotor Fatigue Test Reaction Time

    Reaction time (ms) on the Psychomotor Fatigue Test (PFTT). Lower values indicate faster psychomotor processing.

    Measured: Baseline (Week 0) and post-intervention (Week 6), assessed before and after mental fatigue induction

  8. Psychomotor Fatigue Test Processing Speed

    Processing speed (1000/RT; s-¹) on the PFTT. Higher values indicate faster psychomotor processing.

    Measured: Baseline (Week 0) and post-intervention (Week 6), assessed before and after mental fatigue induction

  9. Psychomotor Fatigue Test Rate Correct Score

    Rate correct score (correct responses·s-¹) on the PFTT. Higher values indicate better integrated speed-accuracy performance.

    Measured: Baseline (Week 0) and post-intervention (Week 6), assessed before and after mental fatigue induction

  10. Task-Switching Test Reaction Time

    Reaction time (ms) on the Task-Switching Test (TSWT). Lower values indicate faster cognitive flexibility.

    Measured: Baseline (Week 0) and post-intervention (Week 6), assessed before and after mental fatigue induction

  11. Task-Switching Test Processing Speed

    Processing speed (1000/RT; s-¹) on the TSWT. Higher values indicate faster cognitive flexibility.

    Measured: Baseline (Week 0) and post-intervention (Week 6), assessed before and after mental fatigue induction

  12. Task-Switching Test Rate Correct Score

    Rate correct score (correct responses·s-¹) on the TSWT. Higher values indicate better integrated speed-accuracy performance.

    Measured: Baseline (Week 0) and post-intervention (Week 6), assessed before and after mental fatigue induction

  13. Time-Load Dual-Back Rate Correct Score

    Rate correct score (correct responses·s-¹) on the 20-minute time-load dual-back (TLDB) mental fatigue induction task.

    Measured: Baseline (Week 0) and post-intervention (Week 6)

  14. Countermovement Jump Peak Landing Force

    Peak landing force (N) assessed via dual force plates (VALD ForceDecks).

    Measured: Baseline (Week 0) and post-intervention (Week 6), assessed before and after mental fatigue induction

  15. Countermovement Jump Reactive Strength Index

    Reactive strength index (m·s-¹) assessed via dual force plates (VALD ForceDecks). Higher values indicate greater neuromuscular efficiency.

    Measured: Baseline (Week 0) and post-intervention (Week 6), assessed before and after mental fatigue induction

  16. Countermovement Jump Concentric Impulse

    Concentric impulse (N·s) assessed via dual force plates (VALD ForceDecks). Higher values indicate greater force application during the propulsive phase.

    Measured: Baseline (Week 0) and post-intervention (Week 6), assessed before and after mental fatigue induction

  17. Pittsburgh Sleep Quality Index - Global Score Change

    Six-week change in PSQI global score stratified by sex and weight status.

    Measured: Change from baseline (Week 0) to post-intervention (Week 6)

  18. Perceived Stress Scale (PSS)

    Perceived psychological stress assessed using the 10-item Perceived Stress Scale (scored 0-40). Higher scores indicate greater perceived stress.

    Measured: Baseline (Week 0) and post-intervention (Week 6)

  19. State-Trait Anxiety Inventory - State Subscale (STAI-S)

    State anxiety assessed using the STAI state subscale (scored 20-80). Higher scores indicate greater anxiety.

    Measured: Baseline (Week 0) and post-intervention (Week 6)

  20. State-Trait Anxiety Inventory - Trait Subscale (STAI-T)

    Trait anxiety assessed using the STAI trait subscale (scored 20-80). Higher scores indicate greater dispositional anxiety.

    Measured: Baseline (Week 0) and post-intervention (Week 6)

  21. Visual Analog Scale for Fatigue (VAS-F)

    Subjective fatigue assessed using a 100 mm visual analog scale. Higher scores indicate greater perceived fatigue.

    Measured: Baseline (Week 0) and post-intervention (Week 6), assessed before and after mental fatigue induction at each visit

  22. NASA Task Load Index (NASA-TLX)

    Multidimensional subjective workload assessed across six subscales: mental demand, physical demand, temporal demand, performance, effort, and frustration (each scored 0-20; total scored 0-120). Higher scores indicate greater perceived workload.

    Measured: Baseline (Week 0) and post-intervention (Week 6), assessed immediately following mental fatigue induction

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted15 Jul 2026
  2. Study start1 Dec 2025
  3. Primary completion19 Mar 2026
  4. Study completion19 Mar 2026

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Supportive care
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
81 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07706283
Sponsor's protocol ID
2368924-3
Status last verified
Jul 2026
First submitted
11 Jul 2026
Last updated
15 Jul 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided: Individual participant data may be made available upon reasonable request to the corresponding author, pending review of the proposed use and confirmation that appropriate data sharing agreements are in place.

Questions about this trial

What is this clinical trial studying?

A study testing Magnesium L-threonate in people with Healthy Adults; Cognitive Performance; Sleep Quality; Neuromuscular Function, run by Barry University at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 15 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Pittsburgh Sleep Quality Index (PSQI) (time frame: Baseline (Week 0) and post-intervention (Week 6)). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Jul 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in